創薬流通市場「薬市楽座」
安土桃山時代に自由取引市場として発展した「楽市楽座」にあやかり、創薬シーズ・技術のマーケットプラットフォームを創薬流通市場、「薬市楽座」と名付けました。このマーケットが楽市楽座のように発展することを願っています。
創薬流通市場である薬市楽座では、弊社がお預かりしている創薬シーズ・技術の情報をリストアップしています。ご興味に応じて検索していただくことが可能です。また、リストのダウンロードも行っていただけます。ご興味のあるものがあれば、お問い合わせボタンをクリックしていただき、弊社へのコンタクトをお願いいたします。追加情報を開示させていただきます。
なお、2019年6月27日より、日本語ページにおける、創薬シーズ、創薬技術の各リスト表記が英語に変更になりました。ダウンロード用のPDF、エクセルファイルは英語ページよりダウンロードできる資料と同一ですので、予めご了承下さいませ。
| 掲載日 | シーズ番号 | 作用機序 | 適応症 | 投与経路 | モダリティ | 開発ステージ | 備考 | |
|---|---|---|---|---|---|---|---|---|
| 19/02/12 | GEM063 | Novel 24hr ibuprofen patch | Local pain in sprains | Local | Small molecule |
Phase 1 completed | High payload: Contains 200 mg ibuprofen, Constant delivery over 24 hours, Class-leading adhesion, Water-resistant, Comfortable to wear and remove Pre-clinical safety studies were completed 2017 with no concerns/issues Phase I PK and sensitisation/irritancy studies were successfully completed in 2018 with no concerns/issues |
問合せ |
| 19/01/11 | GEM009 | BET inhibitor | Cancer, RA | Oral | Small molecule |
Preclinical | Updated on January 11, 2019 More potent enzyme inhibition and anti-tumor activities compared with competitors (more potent than GSK525762A and comparble to ABBV-075). Superior safety profile than competitors (no inhibition on hERG or CYP3A4) and can be applied to RA. Easier manufacturing due to absence of asymmetric carbon. |
問合せ |
| 19/01/11 | GEM003 | Selective glucocorticoid receptor agonist | RA/OA, Please refer to Note | Local | Small molecule |
Preclinical | Updated on January 11, 2019 Expected to reduce unfavorable responses of glucocorticoids by selectivity of action (transrepression>transactivation) Discontinued development for RA/OA. Available for repositioning. Possible indications: Atopic dermatitis, Psoriasis, Asthma, COPD, Inflammatory bowel disease etc. |
問合せ |
| 19/01/11 | GEM002 | Kappa-opioid receptor agonist | Pain/Itching, Please refer to Note | Oral | Small molecule |
Preclinical | Updated on January 11, 2019 Discontinued development for pain because of company strategy. Available for repositioning. Possible indications: Chronic pains (Back pain, Arthritis pain, Cancer pain, Post-herpetic neuralgia, Trigeminal neuralgia etc), Pruritus, Irritable bowel syndrome |
問合せ |
| 19/01/11 | GEM001 | TRPV-1 agonist | Rheumatoid Arthritis, Please refer to Note | Oral | Small molecule |
Phase 2a | Updated on January 11, 2019 Potently inhibits TNF-a production by oral administration. Discontinued development for RA. Available for repositioning. Possible indications: Neuropathic pain, Crohn’s disease, Systemic lupus erythematosus, Cachexia, Acute infectious disease, Allergy, Pyrexia, Anemia, Diabetes, Diseases related TNF-α (Colitis, Psoriasis ets.) |
問合せ |
| 19/01/07 | GEM062 | Cannabinoid-releasing topical formulation (siustained release for about 24 hours) | Chronic pain, Sclerosis, Lupus, others | Topical | Small molecule |
Preclinical | Cannabinoid’s utility: nausea and vomiting during chemotherapy, chronic pain, muscle spasms, epilepsy, sclerosis, lupus, schizophrenia etc. This sustained-release topical formulation has significant potential to help treat these disorders. Preclinical efficacy demonstrated in a cutaneous lupus rodent model using AEA. |
問合せ |
| 19/01/07 | GEM061 | Curcumin-releasing topical formulation (sustained release for about 24 hours) | Please refer to Note | Topical | Small molecule |
Preclinical | Indication: Osteoarthritis, CV disease, chronic inflammatory disease, vascular disease (Sickle Cell) Note: Curcumin’s utility: chronic pain, chronic inflammatory conditions such as osteoarthritis, vascular disease such as Sickle Cell and diabetes. This formulation breaks through the limitations of the poor bioavailability of curcumin with oral administration. Preclinical efficacy demonstrated in an rodent arthritis model and a rodent diabetes model. |
問合せ |
| 19/01/07 | GEM060 | Nitric Oxide-releasing topical formulation (sustained release for over 48 hours) | Please refer to Note | Topical | Small molecule |
Preclinical | Indication: Acne, Atopic Dermatitis, Fungal diseases, Wound healing, Chronic rhinosinusitis, Diabetic foot ulcers, Raynaud’s Phenomenon, Middle-ear infections, Erectile dysfunction, Others Note: NO function: Regulation of the vasculature (vasodilatory), broad spectrum antimicrobial activity, anti-inflammatory, anti-oxidant, wound healing, skin cell maturation and survival etc. Human POC already shown with NO in onychomycosis, genital warts, moscullum contagiosum, pulmonary hypertension, acne, atopic dermatits (preliminary); animal POC demonstrated in over 20 peer-reviewed papers. This formulation breaks through the limitations of sustained NO (topical) delivery. |
問合せ |
| 18/12/27 | GEM059 | Recombinant Human Interleukin-1 Receptor Antagonist | Please refer to Note | IM | Protein |
Phase 1 | Indication: 1: Infection, as manifested by febrile neutropenia, in patients with malignancies receiving chemotherapy drugs. 2: Diarrhea in patients with malignancies receiving chemotherapy drugs. 3. Gout arthritis Note: The world's first multiorgan protection agent for tumor chemotherapy. Inhibits cell cycle progression of normal cells and renders them resistanace to chemotherapy. No effects on tumor growth and their sensitivity to chemotherapy Phase 1 : No dose limiting toxicity, None of subjects presented grade 3 or above chemotherapy-induced neutropenia or diarrhea. Gout arthritis: Well tolerated and safe for patients who are restricted from NSAID, glucocorticoid, or colchicine. |
問合せ |
| 18/12/27 | GEM058 | Increase cellular ATP and promote wound healing | Diabetes foot ulcer | Topical | Small molecule |
Phase 2 | Reducing inflammation of endothelial cells of blood vessels. Increasing cellular ATP and speeding up the healing of wounds by promoting the migration of epithelia cells in the skin of wounds. The arrangement of actin which is essential for cell migration is ATP dependent. Applicable to all kind of wound and low cost treatment Phase 2: The estimated complete closure rate is around 60% (vs placebo 30%) |
問合せ |